MA56179A - Traitement de synucléinopathies - Google Patents

Traitement de synucléinopathies

Info

Publication number
MA56179A
MA56179A MA056179A MA56179A MA56179A MA 56179 A MA56179 A MA 56179A MA 056179 A MA056179 A MA 056179A MA 56179 A MA56179 A MA 56179A MA 56179 A MA56179 A MA 56179A
Authority
MA
Morocco
Prior art keywords
synucleinopathies
treatment
Prior art date
Application number
MA056179A
Other languages
English (en)
Inventor
Nitin Krishnaji Damle
Andrew Michael Goldfine
Sanjaykumar Nandlal Mandhane
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MA56179A publication Critical patent/MA56179A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA056179A 2019-06-11 2020-06-09 Traitement de synucléinopathies MA56179A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201921023164 2019-06-11

Publications (1)

Publication Number Publication Date
MA56179A true MA56179A (fr) 2022-04-20

Family

ID=71094647

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056179A MA56179A (fr) 2019-06-11 2020-06-09 Traitement de synucléinopathies

Country Status (15)

Country Link
US (1) US20220257582A1 (fr)
EP (1) EP3982964A1 (fr)
JP (1) JP2022536331A (fr)
KR (1) KR20220024463A (fr)
CN (1) CN114040763A (fr)
AU (1) AU2020292703A1 (fr)
BR (1) BR112021024835A2 (fr)
CA (1) CA3142899A1 (fr)
CL (1) CL2021003303A1 (fr)
EA (1) EA202193211A1 (fr)
IL (1) IL288797A (fr)
MA (1) MA56179A (fr)
MX (1) MX2021015390A (fr)
PH (1) PH12021553098A1 (fr)
WO (1) WO2020250133A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230301982A1 (en) * 2020-07-31 2023-09-28 Sun Pharma Advanced Research Company Limited N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for treatment of alzheimer's disease
CA3251516A1 (en) 2022-05-02 2023-11-09 Sun Pharma Advanced Research Company Limited Methods of reducing progression of neurodegenerative disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162838A0 (en) 2002-01-04 2005-11-20 Univ Rockefeller Compositions and methods for prevention and treatment peptide-of amyloid- related disorders
CA2479257A1 (fr) 2002-03-21 2003-10-02 Dana-Farber Cancer Institute, Inc. Inhibition de reponses de mort cellulaire induite par stress oxydatif
TWI343806B (en) 2003-07-01 2011-06-21 Nat Health Research Institutes Methods of inhibiting neurodegenerative disease
US8618063B2 (en) 2008-04-09 2013-12-31 The Board Of Trustees Of The University Of Illinois Method for treating a synucleinopathy
US9024021B2 (en) 2011-01-21 2015-05-05 Sun Pharma Advanced Research Company Ltd. Diarylacetylene hydrazide containing tyrosine kinase inhibitors
KR20140022063A (ko) 2011-04-07 2014-02-21 어리어드 파마슈티칼스, 인코포레이티드 신경 변성 질환을 치료하기 위한 방법 및 조성물
CA2911040C (fr) 2012-05-02 2021-11-16 Georgetown University Traitement d'une synucleinopathie au moyen d'inhibiteurs de la tyrosine kinase
EP3267200A4 (fr) * 2015-03-06 2018-08-22 Niigata University Biomarqueur de la démence à corps de lewy
RS63243B1 (sr) * 2016-06-02 2022-06-30 Sun Pharma Advanced Res Co Ltd Lečenje parkinsonove bolesti
WO2018216705A1 (fr) * 2017-05-23 2018-11-29 国立大学法人京都大学 Agent prophylactique et/ou thérapeutique contre des maladies neurodégénératives

Also Published As

Publication number Publication date
EP3982964A1 (fr) 2022-04-20
BR112021024835A2 (pt) 2022-01-18
CA3142899A1 (fr) 2020-12-17
CL2021003303A1 (es) 2022-08-19
PH12021553098A1 (en) 2023-08-14
US20220257582A1 (en) 2022-08-18
MX2021015390A (es) 2022-01-24
EA202193211A1 (ru) 2022-03-30
WO2020250133A1 (fr) 2020-12-17
CN114040763A (zh) 2022-02-11
JP2022536331A (ja) 2022-08-15
KR20220024463A (ko) 2022-03-03
IL288797A (en) 2022-02-01
AU2020292703A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
MA52219A (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
EP3351186A4 (fr) Instrument de traitement endoscopique
IL287904A (en) Combination treatment of arthritic disease
MA47820A (fr) Traitement de la glycogénose de type iii
GB201804514D0 (en) Treatment of pyroptosis
EP3946345A4 (fr) Méthodes de traitement de la douleur neuropathique
EP4076217A4 (fr) Construction de traitement de la syndesmose
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3454793A4 (fr) Bobines de traitement d'anévrisme
EP3347032A4 (fr) Traitement de l'ascite
EP3735209A4 (fr) Traitement de la progression de la myopie
EP4008696A4 (fr) Agent de traitement de surface
EP4001364A4 (fr) Agent de traitement de surface
MA51738A (fr) Composés pour le traitement de la douleur
EP3737363A4 (fr) Méthodes de traitement de maladies inflammatoires chroniques
IL280638A (en) Fat tissue treatment
EP3634370A4 (fr) Traitement des troubles cutanés
MA51525A (fr) Traitement de minéraux
EP3773539A4 (fr) Compositions pour le traitement de la peau
EP3873528A4 (fr) Traitement de rasopathie
GB201804515D0 (en) Treatment of necroptosis
EP3866779A4 (fr) Traitement de maladies neurologiques
EP3849605A4 (fr) Méthodes de traitement de la pancréatite
EP3761982A4 (fr) Traitement de maladies démyélinisantes